GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS)
CNY 12.65
(0.4%)
CNY 12.65
(0.4%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.61 Billion CNY | 34.72% |
| 2022 | 1.2 Billion CNY | 27.94% |
| 2021 | 938.96 Million CNY | 48.99% |
| 2020 | 630.22 Million CNY | -28.69% |
| 2019 | 883.78 Million CNY | 22.35% |
| 2018 | 722.34 Million CNY | 13.16% |
| 2017 | 638.33 Million CNY | 24.04% |
| 2016 | 514.6 Million CNY | 43.33% |
| 2015 | 359.04 Million CNY | 34.53% |
| 2014 | 266.87 Million CNY | 67.5% |
| 2013 | 159.32 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 526.88 Million CNY | 5.85% |
| 2024 Q1 | 417.42 Million CNY | -36.65% |
| 2024 Q2 | 492.49 Million CNY | 17.98% |
| 2023 Q3 | 338.84 Million CNY | 20.29% |
| 2023 Q4 | 658.94 Million CNY | 94.47% |
| 2023 FY | 1.61 Billion CNY | 34.72% |
| 2023 Q1 | 348.97 Million CNY | -28.95% |
| 2023 Q2 | 281.68 Million CNY | -19.28% |
| 2022 Q2 | 271.1 Million CNY | 70.85% |
| 2022 Q1 | 158.68 Million CNY | -51.11% |
| 2022 FY | 1.2 Billion CNY | 27.94% |
| 2022 Q4 | 491.17 Million CNY | 75.2% |
| 2022 Q3 | 280.35 Million CNY | 3.41% |
| 2021 Q4 | 324.58 Million CNY | 36.73% |
| 2021 FY | 938.96 Million CNY | 48.99% |
| 2021 Q2 | 247.82 Million CNY | 91.88% |
| 2021 Q1 | 129.15 Million CNY | -51.56% |
| 2021 Q3 | 237.39 Million CNY | -4.21% |
| 2020 Q4 | 266.64 Million CNY | 226.55% |
| 2020 FY | 630.22 Million CNY | -28.69% |
| 2020 Q2 | 134.55 Million CNY | -8.69% |
| 2020 Q1 | 147.36 Million CNY | -52.82% |
| 2020 Q3 | 81.65 Million CNY | -39.31% |
| 2019 Q1 | 143.05 Million CNY | 0.0% |
| 2019 FY | 883.78 Million CNY | 22.35% |
| 2019 Q4 | 312.32 Million CNY | 39.8% |
| 2019 Q3 | 223.4 Million CNY | 8.98% |
| 2019 Q2 | 204.99 Million CNY | 43.3% |
| 2018 FY | 722.34 Million CNY | 13.16% |
| 2018 Q2 | 188.33 Million CNY | 69.26% |
| 2018 Q1 | 111.27 Million CNY | -44.4% |
| 2017 FY | 638.33 Million CNY | 24.04% |
| 2017 Q1 | 84.21 Million CNY | -47.11% |
| 2017 Q3 | 200.15 Million CNY | 0.0% |
| 2017 Q4 | 200.15 Million CNY | 0.0% |
| 2016 Q4 | 159.22 Million CNY | 0.0% |
| 2016 Q1 | 98.08 Million CNY | -9.87% |
| 2016 Q2 | 98.08 Million CNY | -0.0% |
| 2016 Q3 | 159.22 Million CNY | 62.34% |
| 2016 FY | 514.6 Million CNY | 43.33% |
| 2015 Q3 | 108.82 Million CNY | 53.94% |
| 2015 Q1 | 70.69 Million CNY | -5.48% |
| 2015 Q4 | 108.82 Million CNY | 0.0% |
| 2015 Q2 | 70.69 Million CNY | 0.0% |
| 2015 FY | 359.04 Million CNY | 34.53% |
| 2014 Q3 | 74.79 Million CNY | 27.54% |
| 2014 Q1 | 58.64 Million CNY | 0.0% |
| 2014 FY | 266.87 Million CNY | 67.5% |
| 2014 Q2 | 58.64 Million CNY | 0.0% |
| 2014 Q4 | 74.79 Million CNY | 0.0% |
| 2013 FY | 159.32 Million CNY | 0.0% |